Optimal Duration of Dual Antiplatelet Therapy after Coronary Stent Implantation

Guy Witberg, Eli Lev, Ran Kornowski

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Dual antiplatelet pharmacotherapy reduces ischemic events at the cost of excess bleeding in patients who underwent coronary stenting. The currently recommended treatment period is based on trials held some 20 years ago and not relevant to current clinical practice. In recent years, numerous clinical trials have tried to answer the question of what is the optimal duration of therapy to maximize clinical benefit. These trials showed 2 seemingly conflicting answers - on one hand, shorter treatment duration seems to be safer in reducing bleeding while not increasing ischemic events, and on the other hand, longer duration is superior in terms of preventing ischemic events albeit at the cost of increased bleeding rates. In this review, we summarize the evidence favoring each approach, highlight the limitations of the various pivotal clinical trials in this field, review future directions of research and changes in practice that may influence the duration of antiplatelet therapy, and attempt to propose a personalized approach to achieve maximal benefit for the individual patient.

Original languageEnglish
Pages (from-to)1631-1636
Number of pages6
JournalAmerican Journal of Cardiology
Issue number10
StatePublished - 15 Nov 2015
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Optimal Duration of Dual Antiplatelet Therapy after Coronary Stent Implantation'. Together they form a unique fingerprint.

Cite this